Also found in: Medical, Wikipedia.
CB1Cannabinoid Type 1 (biochemistry)
CB1Circuit Breaker 1 (product code)
CB1Corrected First Born (perturbation theory in atom-ion collisions)
CB1Clinical Building 1 (University of Texas Southwestern Medical Center)
CB1Coxsackie Virus B1 (cardiology research)
References in periodicals archive ?
According to Krystal, the findings raise the possibility that normalizing cannabinoid CB1 receptor activity might play a role in reducing cannabis use and problems with impulse control in users.
The main active ingredient in cannabis, THC, acts on the brain through CB1 cannabinoid receptors located in the neurons.
Mice that were genetically engineered to lack CB1 experienced considerably increased nerve degeneration.
A continuacion, se eliminaron las peroxidasas endogenas del tejido y despues se incubo con el anticuerpo primario contra el receptor a canabinoides CB1 a una dilucion de 1:5000 (CB1 hecho en conejo; USBiological), y suero normal de cabra al I % (Vector Laboratories) en PBT (0.
Peripheral CB1 antagonists developed at Jenrin have been shown to help reduce body weight, decrease fatty liver, and lower serum levels of insulin and triglycerides in mice exposed to a high-fat diet.
Blockade of these receptors by selective CB1 receptor antagonists causes weight loss and ameliorates risk factors for obesity related disorders such as cardiovascular disease and type II diabetes.
50]) for the newly developed CB1 black has comparatively larger aggregate size (81 nm) compared to regular HAF blacks (68-75 nm) and lower compared to N660 (190 nm).
Studies using CB1 receptor knock-out mice have shown that without the CB1 receptor, animals are unresponsive to cannabinoids (Ledent, Valerde, Cossu, Petitet, Aubert, Beslot, Bohme, Imperato, Pedrazzini, Roques, Vassart, Fratta & Parmentier, 1999; Steiner, Bonner, Zimmer, Kitai & Zimmer, 1999; Zimmer, Zimmer, Hohmann, Herkenham & Bonner, 1999).
But CB1 came to life with its contrasting profusion of foliage, changing light and gorgeously rich collection of art.
The Competitive Intelligence Report Cannabinoid-1 (CB1) Receptor Antagonists as of November 2008 provides a competitor analysis in the development pipeline of novel CB1 receptor antagonists for treatment of obesity, type 2 diabetes and CNS diseases.
Molecules that target CB1 receptors may have promise in treating a variety of conditions such as pain, inflammation, obesity, nerve cell diseases, and substance use disorders.